Oral ranitidine and duration of gastric pH >4.0 in infants with persisting reflux symptoms

Silvia Salvatore1, Bruno Hauser, Alessandro Salvatoni

  • 1Clinica Pediatrica di Varese, Università dell'Insubria, Varese, Italy.

Insights

Ranitidine treatment for infant gastro-oesophageal reflux (GOR) may not always be effective. Some infants require better acid suppression or their symptoms may not be acid-related.

Area of Science:

  • Pediatric Gastroenterology
  • Pharmacology
  • Clinical Medicine

Background:

  • Ranitidine is frequently used for pathological gastro-oesophageal reflux (GOR) in infants.
  • Limited data exist on ranitidine's effect on esophageal acid exposure and gastric acid reduction in this population.
  • Non-responsiveness to ranitidine in infants with GOR has been reported.

Purpose of the Study:

  • To evaluate esophageal acid exposure in infants with GOR who do not respond to ranitidine.
  • To assess the reduction in gastric acid secretion with ranitidine treatment.
  • To examine the histology of esophageal biopsies in non-responsive infants.

Main Methods:

  • 103 infants with persisting reflux symptoms despite ranitidine treatment were studied.
  • A mean ranitidine dose of 9.4 mg/kg/d was administered for at least 2 weeks.
  • A 24-hour pH study and esophageal biopsy (in 90/103 infants) were performed.

Main Results:

  • Histological esophagitis was found in 23% of infants.
  • The esophageal reflux index (RI) was elevated (>5%) in 20% of infants.
  • Ranitidine dosage showed a weak correlation with esophageal RI (p=0.05) but not with gastric pH control.

Conclusions:

  • Some infants with presumed GOR symptoms do not respond to ranitidine.
  • This lack of response may be due to inadequate acid suppression.
  • Alternatively, symptoms might not be primarily acid-related in these infants.
Abstract

Related Concept Videos

Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids01:31

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids

In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...